Demonstrated Favorable Safety Profile of REQORSA AUSTIN, Texas, Oct. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today...Read more
Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif., Oct. 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a...Read more
U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular...Read more
The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen Results of the pivotal Phase 3 LUNAR trial represent the first...Read more
PDUFA goal date set for June 13, 2025 UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC, if approved PRINCETON, N.J. / Oct 15, 2024 / Business Wire / UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat...Read more
GPS Currently Investigated in Phase 3 REGAL Trial in Adult AML Patients – Interim Analysis Anticipated in Q4 2024 RPDD Provides Eligibility for GPS to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties Recent Valuations for...Read more
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Bright Minds Biosciences | 36.00 1,445.78 | $38.49 |
| ZIVO Bioscience | 18.90 1,718.18 | $20.00 |
| Finch Therapeutics | 10.20 566.67 | $12.00 |
| Jazz Pharmaceuticals | 6.25 5.63 | $117.28 |
| HCA Healthcare | 5.48 1.38 | $401.26 |
| Tenet Healthcare | 4.96 3.19 | $160.25 |
| Univerl Health Services | 4.89 2.22 | $225.34 |
| Crinetics Pharmaceuticals | 4.50 8.47 | $57.60 |
| McKesson | 4.39 0.86 | $513.67 |
| Alnylam Pharmaceuticals | 4.04 1.43 | $287.36 |
| Janux Therapeutics | 3.39 6.87 | $52.74 |
| Arcellx | 3.10 3.57 | $89.91 |
| Globus Medical | 2.86 4.02 | $74.05 |
| Waters | 2.75 0.77 | $360.00 |
| DaVita | 2.74 1.69 | $164.57 |
| Inari Medical | 2.66 6.30 | $44.86 |
| Harrow | 2.60 5.11 | $53.49 |
| Johnson & Johnson | 2.50 1.55 | $164.10 |
| Company | Volume | Last Trade |
|---|---|---|
| Gritstone bio | 348,093,732 | $0.07 |
| Bright Minds Biosciences | 98,035,273 | $38.49 |
| Walgreens Boots Alliance | 88,274,390 | $10.42 |
| Vyome | 36,361,564 | $0.22 |
| Lipella Pharmaceuticals | 29,339,061 | $0.43 |
| Immuneering | 25,621,400 | $2.31 |
| Pfizer | 21,729,600 | $29.44 |
| Rani Therapeutics | 19,771,054 | $2.12 |
| Enveric Biosciences | 19,379,621 | $0.42 |
| Aditxt | 17,945,973 | $1.12 |
| CVS Health | 14,897,220 | $65.00 |
| Hoth Therapeutics | 11,527,638 | $0.89 |
| UnitedHealth | 11,099,142 | $556.29 |
| PacBio | 8,514,827 | $2.10 |
| Johnson & Johnson | 8,502,958 | $164.10 |
| 23andMe | 8,476,809 | $0.27 |
| Tonix Pharmaceuticals | 8,473,580 | $0.14 |
| Exelixis | 8,387,922 | $28.50 |
| Bristol-Myers Squibb | 7,931,301 | $52.76 |
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
